We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+8.72%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$58.1M
AUM Growth
-$17.9M
Cap. Flow
-$4.42M
Cap. Flow %
-7.61%
Top 10 Hldgs %
43.93%
Holding
340
New
63
Increased
59
Reduced
56
Closed
151

Top Buys

1
CLVS
Clovis Oncology, Inc.
CLVS
+$2.31M
2
AMGN icon
Amgen
AMGN
+$1.97M
3
IBB icon
iShares Biotechnology ETF
IBB
+$1.79M
4
TSRO
TESARO, Inc.
TSRO
+$1.56M
5
CLX icon
Clorox
CLX
+$1.3M

Top Sells

1
ABT icon
Abbott
ABT
+$5.02M
2
AKBA icon
Akebia Therapeutics
AKBA
+$3.63M
3
FL
Foot Locker
FL
+$2.12M
4
GIS icon
General Mills
GIS
+$2.03M
5
LULU icon
lululemon athletica
LULU
+$1.38M

Sector Composition

1 Healthcare 37.51%
2 Consumer Staples 17.11%
3 Consumer Discretionary 2.69%
4 Communication Services 1.36%
5 Materials 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LUMO
301
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-3,085
Closed -$669K
ALPN
302
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-5,361
Closed -$63K
PRTK
303
CALL
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-27,500
Closed -$55K
PRTK
304
PUT
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-38,000
Closed -$9K
ACOR
305
PUT
DELISTED
Acorda Therapeutics
ACOR
– –
-500
Closed -$32K
CNCE
306
CALL
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-10,000
Closed -$2K
XLNX
307
CALL
DELISTED
Xilinx Inc
XLNX
– –
-12,500
Closed -$2K
XLNX
308
DELISTED
Xilinx Inc
XLNX
– –
-7,020
Closed -$406K
XLNX
309
PUT
DELISTED
Xilinx Inc
XLNX
– –
-11,700
Closed -$29K
DNKN
310
CALL
DELISTED
Dunkin' Brands Group, Inc.
DNKN
– –
-27,100
Closed -$28K
APC
311
CALL
DELISTED
Anadarko Petroleum
APC
– –
-11,000
Closed -$1K
APC
312
DELISTED
Anadarko Petroleum
APC
– –
-12,000
Closed -$744K
APC
313
PUT
DELISTED
Anadarko Petroleum
APC
– –
-12,000
Closed -$125K
SGYP
314
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-15,000
Closed -$70K
SGYP
315
PUT
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-40,000
Closed -$18K
OCLR
316
CALL
DELISTED
Oclaro Inc.
OCLR
– –
-9,500
Closed -$5K
OCLR
317
DELISTED
Oclaro Inc.
OCLR
– –
-1,300
Closed -$13K
OCLR
318
PUT
DELISTED
Oclaro Inc.
OCLR
– –
-6,600
Closed -$4K
COL
319
DELISTED
Rockwell Collins
COL
– –
-13,000
Closed -$1.26M
COL
320
PUT
DELISTED
Rockwell Collins
COL
– –
-13,000
Closed -$10K
MON
321
PUT
DELISTED
Monsanto Co
MON
– –
-5,100
Closed -$3K
AVXS
322
PUT
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-100
Closed -$1K
BWLD
323
CALL
DELISTED
Buffalo Wild Wings, Inc.
BWLD
– –
-20,000
Closed -$26K
BWLD
324
DELISTED
Buffalo Wild Wings, Inc.
BWLD
– –
-2,573
Closed -$393K
BWLD
325
PUT
DELISTED
Buffalo Wild Wings, Inc.
BWLD
– –
-15,200
Closed -$94K
10 11 12
13
14

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q2 2017 Portfolio in Review

As of Q2 2017, FT Options held 340 positions worth $58.1M, down 24% from $76M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

FT Options withdrew a net $4.42M in Q2 2017, closing 151 positions and reducing 56 holdings. Its most notable exit was Foot Locker, an estimated $2.12M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 35% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, FT Options opened a new position in Amgen worth $2.08M.

  • FT Options's largest Q2 2017 buy was Amgen: 12,082 shares worth $2.08M.
  • FT Options added most to Clovis Oncology, Inc. in Q2 2017, an estimated $2.31M increase.
  • FT Options's biggest Q2 2017 reduction was Abbott, cutting an estimated $5.02M.
  • FT Options fully exited Foot Locker in Q2 2017, selling an estimated $2.12M.
  • FT Options's ten largest holdings make up 44% of its $58.1M portfolio in Q2 2017.
  • FT Options opened 63 new positions and closed 151 in Q2 2017.
  • FT Options's portfolio value fell 24% quarter-over-quarter to $58.1M.

Based on FT Options's 13F filing for Q2 2017, filed 11 Aug 2017.